Sign in
Taking people in United StatesNo phase

Tracks medicine adherence and symptoms in people with inflammatory bowel disease

Studies a remote monitoring tool in adults taking vedolizumab for bowel disease.

Key facts

Who runs it
Mercy Medical Center
Where
Chapel Hill, Chevy Chase, Cincinnati, Nashville, New Orleans, and New York, United StatesSee the 6 sites
Trial code
Registry title
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
Status
Recruiting
People taking part
200 people, planned
Started
5 May 2025
Expected to end
30 Sept 2027
Type of study
Observational
Treatments tested
  • Tappt
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Crohn's disease or ulcerative colitis who are starting vedolizumab and have a smartphone for remote monitoring.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Documented inflammatory bowel disease (IBD), confirmed by symptoms, endoscopy, radiology and histology.
Earlier treatment
People must be starting treatment with vedolizumab.

Main reasons for not taking part

  • Cannot read and speak English or Spanish
  • No smartphone with reliable data or Wi-Fi
  • Has an ileostomy, colostomy, ileoanal pouch or ileorectal anastomosis
  • Surgery planned within the next 60 days
  • History of short bowel syndrome

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • At least 18 years of age or older
  • Have documented IBD based on usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology
  • Initiating treatment with vedolizumab
  • Have access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access
  • Ability to understand the protocol and provide informed consent in English or Spanish

Who cannot take part

  • Imminent surgery (within the next 60 days)
  • History of short bowel syndrome
  • Uncontrolled medical or psychiatric disease at the opinion of the investigator; Degenerative neurologic condition; Unstable angina; Symptomatic peripheral vascular disease; Malignancy within the last 2 years (excluding squamous or basal cell cancers of the skin); Poorly controlled depression, mania, and schizophrenia; Serious active infection requiring antimicrobial therapy (excluding CD patients with perianal CD on antibiotics)
  • Inability to speak and read English or Spanish
  • Unable to comply with the study protocol including inability to access the internet and/or inadequate access to a smart device
  • Unable to access vedolizumab due to insurance restrictions
  • Unable to follow up at respective sites due to insurance restrictions or other barriers (i.e., distance from patient's home to study site)
  • Presence of an ileostomy, colostomy, ileoanal pouch anastomosis, or ileorectal anastomosis

Where in United States

  • University of North CarolinaChapel Hill, United StatesContact: Emily EnglishTaking people
  • Capital Digestive CareChevy Chase, United StatesContact: Gilbert HorstNot yet recruiting
  • University of CincinnatiCincinnati, United StatesContact: Renee HenryNot yet recruiting
  • Vanderbilt UniversityNashville, United StatesContact: Michael McGillNot yet recruiting
  • Tulane UniversityNew Orleans, United StatesContact: Lauren Griffin-ScudariNot yet recruiting
  • NYU Langone HealthNew York, United StatesContact: Nathasha MelukkaranTaking people

About the trial

What the trial wants to find out

The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, and inflammatory bowel disease type undetermined) initiating therapy with vedolizumab (Entvyio). The main questions it aims to answer are:

Read full original descriptionShow less

1. Assess and compare adherence to intravenous (IV) and subcutaneous vedolizumab maintenance therapy in patients with IBD using a novel remote monitoring system. 2. Assess symptom response to vedolizumab post induction (week 6-8) and during maintenance therapy (week 22) using a novel remote monitoring system. 3. Assess time to response to vedolizumab during induction (weeks 0-6) using a novel remote monitoring system.

Researchers will compare medication adherence between participants using IV and subcutaneous vedolizumab maintenance therapy to see if adherence is lower with self-administration.

Participants will be asked to register adherence to medication using the novel remote monitoring system each time they take a dose of vedolizumab and to respond to two questions about bowel symptoms weekly for the first 6 weeks after starting vedolizumab then monthly thereafter for 6 months. Additionally, participants will be asked to enter information regarding demographics and social determinants of health at baseline and other variables listed below at baseline and at weeks 2, 6, 14, and 22 post baseline unless otherwise denoted:

* MARS-5 * Healthcare utilization (22 weeks only) * Harvey Bradshaw Index (Crohn's disease only) * Simple clinical colitis activity index (Ulcerative colitis only) * PROMIS Global Health Scale * PROMIS Anxiety * PROMIS Depression * PROMIS Sleep Disturbance * PROMIS Pain Interference * PROMIS Physical Function * IBD Self-Efficacy * Attitudinal Survey (22 weeks only)

The group in the trial

  • Participants with IBD receiving vedolizumab

    Treatment: Tappt

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real World Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention (MONITOR Study)
Plain-language title
Tracks medicine adherence and symptoms in people with inflammatory bowel diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 October 2026